Century Therapeutics, Inc.
Income Statement
| Line Item | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $109.2M | $4.2M | $791.0K | $771.0K | $855.0K | $268.0K | $148.0K | $99.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $8.4M | $7.8M | $8.4M | $8.3M | $8.7M | $8.6M | $9.0M | $8.2M |
| Operating Income | $74.2M | $-37.3M | $-34.8M | $-34.8M | $-31.3M | $-43.8M | $-35.6M | $-35.1M |
| Operating Margin | 67.9% | -893.7% | -4,398.1% | -4,507.8% | -3,661.9% | -16,329.1% | -24,071.6% | -35,431.3% |
| Interest Expense | — | — | — | — | — | — | — | $136.0K |
| Pretax Income | $76.6M | $-34.3M | $-31.2M | $-31.2M | $-28.1M | $-40.3M | $-32.1M | $-32.3M |
| Income Tax Expense | — | $1.8M | $-8.0K | $22.0K | $1.0K | $-869.0K | $592.0K | $950.0K |
| Net Income | $76.6M | $-36.1M | $-31.2M | $-31.2M | $-28.1M | $-39.4M | $-32.7M | $-33.3M |
| Net Margin | 70.1% | -864.6% | -3,947.7% | -4,047.6% | -3,282.1% | -14,700.7% | -22,108.1% | -33,627.3% |
| EPS (Basic) | $0.89 | $-0.41 | $-0.37 | $-0.38 | $-0.45 | $-0.66 | $-0.55 | $-0.56 |
| EPS (Diluted) | $0.89 | $-0.41 | $-0.37 | $-0.38 | $-0.45 | $-0.66 | $-0.55 | $-0.56 |
| Shares Outstanding (Basic) | 86.0M | 78.6M | 84.7M | 82.1M | 62.3M | 59.3M | 59.4M | 59.3M |
| Shares Outstanding (Diluted) | 86.1M | 78.6M | 84.7M | 82.1M | 62.3M | 59.3M | 59.4M | 59.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |